Publications by authors named "J Spacek"
Article Synopsis
- Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder often leading to end-stage renal disease, and this study reviews native nephrectomy (NN) practices over 25 years at a transplant center.
- A total of 89 out of 152 ADPKD patients who underwent kidney transplantation (KT) also had NN, with most NN being unilateral and planned surgeries showing better outcomes than acute ones.
- The findings highlight the importance of careful planning and patient-specific strategies in NN for ADPKD due to increased complications associated with acute surgeries.
Aim: A retrospective audit from a urological center focused on urological fistulas that directly connect with the treatment of gynecological malignancy. Ureteroarterial fistulas, i.e.
View Article and Find Full Text PDFObjective: To investigate DNA methylation of specific tumor suppressor genes in endometrial hyperplasia compared to normal endometrial tissue. File and methodology: To search for epigenetic events, methylation-specific multiplex ligation-dependent probe amplification was employed to compare the methylation status of 40 tissue samples with atypical endometrial hyperplasia, 40 tissue samples with endometrial hyperplasia without atypia, and 40 control tissue samples with a normal endometrium.
Results And Conclusion: Differences in DNA methylation among the groups were found in TWIST1, GATA4, MUS81, and NTRK1 genes (TWIST1: atypical hyperplasia 67.
High-grade serous ovarian carcinoma (HGSC) is the most common subtype of ovarian cancer and is among the most fatal gynecological malignancies worldwide, due to late diagnosis at advanced stages and frequent therapy resistance. In 47 HGSC patients, we assessed somatic and germline genetic variability of a custom panel of 144 known or suspected HGSC-related genes by high-coverage targeted DNA sequencing to identify the genetic determinants associated with resistance to platinum-based therapy. In the germline, the most mutated genes were DNAH14 (17%), RAD51B (17%), CFTR (13%), BRCA1 (11%), and RAD51 (11%).
View Article and Find Full Text PDFPurpose: Immune checkpoint inhibitors (ICIs) dramatically changed the prognosis of patients with NSCLC. Unfortunately, a reliable predictive biomarker is still missing. Commonly used biomarkers, such as PD-L1, MSI, or TMB, are not quite accurate in predicting ICI efficacy.
View Article and Find Full Text PDF